Greater Certainty in Genetic Testing Results at HCM Specialty Centers

A recent study carried out by scientists who are part of the SHaRe Cardiomyopathy Registry found that genetic testing results for HCM are more helpful and definitive when carried out at a high volume HCM center, especially one who shares data with other centers specializing in HCM. 

Septal Reduction – Not a One Size Fits All

A recent article published in the European Journal of Cardiology Heart Failure compares septal myectomy to septal alcohol ablation. The article emphasizes that proper patient selection for either procedure is key.

Seniors Do Well After Myectomy

A recent study of Medicare patients conducted by doctors at the Cleveland Clinic found that senior citizens who underwent septal myectomy had better long term survival and did not need repeat procedures compared to those who underwent septal alcohol ablation.

Myectomy: Still the Gold Standard for HOCM

An expert panel comprised of many of the world’s top HCM experts recently published a retrospective analysis which looked at septal myectomy over the last 60 years of practice. It concludes that myectomy remains the best treatment for patients with obstructive hypertrophic cardiomyopathy.

VALOR-HCM Trial – Mavacamten vs. Septal Reduction Therapy – RESULTS ARE IN!

The Phase 3 VALOR-HCM trial results were presented this morning at the American College of Cardiology annual meeting in Washington, DC by the principal investigator, Dr. Milind Desai of the Cleveland Clinic, and the results are good!

HCM Researchers Put their Heads Together to Improve Lives of HCM Patients

A recent study looked at what researchers claim is the largest cohort of HCM patients ever studied. This study found that HCM patients are at substantially elevated risk for atrial fibrillation and heart failure, and have significantly higher mortality rates than that of the general U.S. population. Therefore, the researchers conclude, there is much more work needed in order to solve the riddle of HCM.

Cardiac MRI Helps Assess Sudden Death Risk

A recent study by doctors at the Cleveland Clinic suggests that the presence of late gadolinium enhancement  (LGE) should be added to the various risk factors currently used to assess patients who are at low or intermediate risk of sudden death.